Severe COVID-19 Infection in Children Presenting to EDs in Israel and England

Condition(s) studied

Investigational drug(s) / intervention(s)

Nasopharyngeal swab sampling for COVID-19: The healthcare provider will gently insert the swab a short distance (1-1.5 cm for young children) into one nostril, reaching the back of the nasal cavity. The swab will then be gently rotated and rubbed for a few seconds to collect a sample of mucus. The same process may be repeated in the other nostril.

Study summary

Even though the COVID-19 pandemic is no longer at its peak, the threat still lingers. Engaging in prospective surveillance studies will enable us to monitor the disease and prepare for any potential resurgence. COVID-19 surveillance studies are essential tools for policymakers to make informed decisions, allocate resources, and develop strategies to control the spread of the virus and protect public health.

The objective of this surveillance study is to prospectively assess in-hospital severe morbidity related to COVID-19 infection in children who present to the Pediatric Emergency Department (ED).

A prospective multicenter study will be conducted across eight EDs in Israel and five EDs in the United Kingdom. The study population will include children aged 16 years or younger with a severe acute COVID-19 infection. Confirmation of acute COVID-19 infection will be based on polymerase chain reaction nasopharyngeal swab testing. The study will also include patients diagnosed with multisystem inflammatory syndrome in children (MIS-C), as defined by the CDC.

Eligibility

Primary outcome measure(s)

• Severe acute COVID-19 infection (SACI) — Up to 16 weeks
  The percentage of patients diagnosed with SACI among all patients admitted to the Emergency Department

Trial sites (6)

More Hadassah Medical Organization trials in Israel

Other trials for the same condition